BMY250502P71000
- 21.00
- 0.000.00%
Bristol-Myers Squibb Newsroom
The Strong Earnings Posted By Bristol-Myers Squibb (NYSE:BMY) Are A Good Indication Of The Strength Of The Business
Piper Sandler Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Raises Target Price to $66
Piper Sandler Adjusts Bristol-Myers Squibb's Price Target to $66 From $65
Express News | UK's Mhra: Approved New Under-the-Skin Injection Version of Nivolumab (Opdivo)
Express News | UK's Mhra: Authorises Cancer Treatment Variation With an Administration Time of 3–5 Minutes - Website
Bristol-Myers Squibb Exec Makes Bold Stock Purchase!
Is Bristol-Myers Squibb Company (BMY) the Best Long-Term Dividend Stock to Buy According to Billionaires?
Sandoz Inks Agreement With Shanghai Henlius for Bristol Yervoy Biosimilar
Pfizer Stock Falls After Earnings Beat. Tariffs Aren't the Only Worry. -- Barrons.com
Pfizer Hints at Acquisitions to Boost Obesity Pipeline After Trial Setback
Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $48 From $54, Maintains Neutral Rating
Wells Fargo Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $53
Pfizer Reports Earnings as Stock Sits in Doldrums -- Barrons.com
Top 3 Health Care Stocks That May Rocket Higher In April
Goldman Sachs: The Q1 performance of U.S. pharmaceutical stocks is reassuring, and the Industry sentiment is slightly becoming more positive.
Goldman Sachs stated that amid cautious sentiment from investors towards the USA pharmaceutical sector before the Earnings Reports season, the performance of USA pharmaceutical companies that have reported results so far for the first quarter has not been worse than expected, and in some cases, it has even exceeded expectations.
Express News | Bristol-Myers Squibb : HSBC Cuts Target Price to $47 From $56
Notable Healthcare Headlines for the Week: Merck, Roche and Bausch Health in Focus
Is Bristol-Myers Squibb Company (NYSE:BMY) A High Quality Stock To Own?
Bristol-Myers Squibb First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $56 From $55, Maintains Neutral Rating